ITM and Lumara Bio Will Present Cancer Study Data
The companies plan to share Phase 3 trial findings during the 2026 ASTRO meeting in Boston.
Updated on Sept. 23, 2026 in Cancer
ITM and Lumara Bio will hold two poster presentations on the treatment 177Lu-edotreotide at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The sessions are set to take place in Boston on September 27, 2026.
Why it matters
The findings highlight results from the Phase 3 COMPETE trial, which successfully reached its primary endpoint regarding progression-free survival in patients with neuroendocrine tumors. These presentations offer new insight into dosimetry and potential re-treatment protocols for the therapy.
The dosimetry results will be featured in abstract number 2100, while the registry analysis on re-treatment is covered in abstract 2066. Both posters will be displayed at board number 27 in the Exhibit Hall.
The players
ITM
ITM is a biotechnology company headquartered in Garching near Munich that focuses on the development of targeted radiopharmaceuticals.
Lumara Bio
Lumara Bio is a life sciences company that collaborates on the research and development of diagnostic and therapeutic oncology products.
The details
The presentations scheduled for September 27 will detail findings from the COMPETE study, which compared the efficacy of 177Lu-edotreotide against everolimus. Additionally, the researchers will share insights from a registry analysis regarding the safety and utility of re-treatment with the therapy.
Timeline
The 2026 ASTRO Annual Meeting takes place in Boston from September 26 to September 30, 2026.
The poster presentations are scheduled for September 27, 2026, from 3:00 to 4:00 PM ET.
The Big Picture
The COMPOSE Phase 3 study represents the next stage of development for the technology following the results presented at ASTRO. This research builds upon the COMPETE trial, further testing the efficacy of targeted radiopharmaceuticals in oncology.
The findings provide oncologists and patients with neuroendocrine tumors with more data regarding treatment efficacy and safety protocols. These results may influence future clinical decision-making and standard-of-care options for patients managing these tumor types.
The takeaway
These presentations mark a significant milestone in validating the use of targeted radiopharmaceuticals for complex tumor treatments. Patients and providers should look for further data as ITM continues its clinical evaluations in the ongoing COMPOSE study.
Further reading
Learn more about the latest developments in the field at the Cancer section.
